Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111862217 | 11186221 | 7 | F | 20150504 | 20160628 | 20150612 | 20160705 | EXP | CA-GILEAD-2015-0157128 | GILEAD | 43.00 | YR | A | M | Y | 77.55000 | KG | 20160705 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111862217 | 11186221 | 1 | PS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD | 21752 | 1 | DF | TABLET | QD | ||||||
| 111862217 | 11186221 | 2 | C | CIPRALEX | ESCITALOPRAM OXALATE | 1 | Oral | 20 MG, UNK | 0 | 20 | MG | ||||||||
| 111862217 | 11186221 | 3 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | Oral | 300 MG, UNK | 0 | 300 | MG | ||||||||
| 111862217 | 11186221 | 4 | C | VITAMIN B COMPLEX | CYANOCOBALAMINDEXPANTHENOLNIACINAMIDEPYRIDOXINE HYDROCHLORIDERIBOFLAVIN 5'-PHOSPHATE SODIUMTHIAMINE HYDROCHLORIDEVITAMIN B COMPLEX | 1 | Oral | UNK, QD | 0 | 1 | DF | QD | |||||||
| 111862217 | 11186221 | 5 | C | MULTIVITAMIN /00097801/ | VITAMINS | 1 | Oral | 1 DF, QD | 0 | 1 | DF | QD | |||||||
| 111862217 | 11186221 | 6 | C | SOYA LECITHIN | DIETARY SUPPLEMENT | 1 | Oral | 2 DF, QD | 0 | 2 | DF | QD | |||||||
| 111862217 | 11186221 | 7 | C | GLUCOSAMINE CHONDROITIN MSM | 2 | 0 | |||||||||||||
| 111862217 | 11186221 | 8 | C | 5-HTP /00439301/ | 2 | Oral | 2 DF, QHS | 0 | 2 | DF | QD | ||||||||
| 111862217 | 11186221 | 9 | C | REACTINE /00884302/ | CETIRIZINE HYDROCHLORIDE | 1 | Oral | 5 MG, PRN | 0 | 5 | MG | ||||||||
| 111862217 | 11186221 | 10 | C | SENOKOT-S | DOCUSATE SODIUMSENNOSIDES | 1 | Oral | 2 DF, QHS | 0 | 2 | DF | QD | |||||||
| 111862217 | 11186221 | 11 | C | PROBIOTIC /06395501/ | BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS | 1 | Oral | 1 DF, QHS | 0 | 1 | DF | QD | |||||||
| 111862217 | 11186221 | 12 | C | ZOPICLONE | ZOPICLONE | 1 | Oral | 7.5 MG, QHS | 0 | 7.5 | MG | QD | |||||||
| 111862217 | 11186221 | 13 | C | VIMOVO | ESOMEPRAZOLE MAGNESIUMNAPROXEN | 1 | UNK, PRN | 0 | |||||||||||
| 111862217 | 11186221 | 14 | C | TYLENOL | ACETAMINOPHEN | 1 | UNK, PRN | 0 | |||||||||||
| 111862217 | 11186221 | 15 | C | VALACYCLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | Unknown | UNK UNKNOWN, PRN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111862217 | 11186221 | 1 | Prophylaxis against HIV infection |
| 111862217 | 11186221 | 2 | Depression |
| 111862217 | 11186221 | 3 | Depression |
| 111862217 | 11186221 | 15 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111862217 | 11186221 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111862217 | 11186221 | Drug ineffective | |
| 111862217 | 11186221 | HIV infection | |
| 111862217 | 11186221 | Multiple-drug resistance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111862217 | 11186221 | 1 | 201304 | 0 | ||
| 111862217 | 11186221 | 2 | 2009 | 0 | ||
| 111862217 | 11186221 | 3 | 201402 | 0 | ||
| 111862217 | 11186221 | 15 | 201304 | 0 |